Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.

We evaluated whether ivermectin combined with doxycycline reduced the clinical recovery time in adults with COVID-19 infection. This was a randomized, blinded, placebo-controlled trial in patients with mild-to-moderate COVID-19 symptoms randomly assigned to treatment (n = 200) and placebo (n = 200) groups. The primary outcome was duration from treatment to clinical recovery. Secondary outcomes were disease progression and persistent COVID-19 positivity by RT-PCR. Among 556 screened patients, 400 were enrolled and 363 completed follow-up. The mean patient age was 40 years, and 59% were men. The median recovery time was 7 (4-10, treatment group) and 9 (5-12, placebo group) days (hazard ratio, 0.73; 95% confidence interval, 0.60-0.90). The number of patients with a ≤7-day recovery was 61% (treatment group) and 44% (placebo groups) (hazard ratio, 0.06; 95% confidence interval, 0.04-0.09). The proportion of patients who remained RT-PCR positive on day 14 and whose disease did not progress was significantly lower in the treatment group than in the placebo group. Patients with mild-to-moderate COVID-19 infection treated with ivermectin plus doxycycline recovered earlier, were less likely to progress to more serious disease, and were more likely to be COVID-19 negative by RT-PCR on day 14. ClinicalTrials.gov Identifier: NCT04523831. Dryad. doi:10.5061/dryad.qjq2bvqf6.

Citation

Reaz Mahmud, Md Mujibur Rahman, Iftikher Alam, Kazi Gias Uddin Ahmed, A K M Humayon Kabir, S K Jakaria Been Sayeed, Mohammad Aftab Rassel, Farhana Binte Monayem, Md Shahidul Islam, Mohammad Monirul Islam, Anindita Das Barshan, Mohammad Mahfuzul Hoque, Md Uzzal Mallik, Mohammad Abdullah Yusuf, Mohammad Zaid Hossain. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. The Journal of international medical research. 2021 May;49(5):3000605211013550

Mesh Tags

Substances

PMID: 33983065

search → result